Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of $0.09, $0.03 better than the analyst estimate of $0.06. Revenue for the quarter came in at $179.6 million versus the consensus estimate of $171.37 million.

GUIDANCE:

Tandem Diabetes sees FY2021 revenue of $685-695 million, versus the consensus of $684 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.